References

Data from ENROLL-HD: is the prevalence of juvenile and pediatric Huntington’s disease overestimated?

10.1016/j.parkreldis.2021.05.012 · 2021 · External reference

Guofang Xue, The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets

10.3389/fnagi.2024.1347987 · 2024 · External reference

Mitochondria and reactive oxygen species

10.1161/hypertensionaha.109.130054 · 2009 · External reference

RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA

10.1186/s40035-017-0101-9 · 2017 · External reference

Unresolved reference

2025 · External reference

CRISPR/Cas9 Mediated Therapeutic Approach in Huntington’s Disease

10.1007/s12035-022-03150-5 · 2023 · External reference

Astrocyte-neuron metabolic relationships: for better and for worse

10.1016/j.tins.2010.12.001 · 2011 · External reference

A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system

10.1038/s41587-019-0205-0 · 2019 · External reference

Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks

10.1016/j.jconrel.2023.07.027 · 2023 · External reference

Clinical management of neuropsychiatric symptoms of huntington disease: expert-based consensus guidelines on agitation, anxiety, apathy, psychosis and sleep disorders

10.3233/jhd-180293 · 2018 · External reference

Psychotropic medication use in Huntington’s disease: a retrospective cohort study

10.1016/j.parkreldis.2022.11.004 · 2022 · External reference

Rapid eye movement sleep disturbances in Huntington disease

10.1001/archneur.65.4.482 · 2008 · External reference

Juvenile Parkinson’s disease and its response to L-dopa therapy

10.1007/bf02251243 · 1990 · External reference

International guidelines for the treatment of Huntington’s disease

10.3389/fneur.2019.00710 · 2019 · External reference

The frequency of huntington disease and huntington disease-like 2 in the South African population

10.1159/000444020 · 2016 · External reference

Prevalence of juvenile-onset and pediatric Huntington’s disease and their availability and ability to participate in trials: a Dutch population and Enroll-HD observational study

10.3233/jhd-240034 · 2024 · External reference

Juvenile-Onset Huntington Disease Pathophysiology and Neurodevelopment: a Review

10.1002/mds.28823 · 2022 · External reference

Disassociation of histone deacetylase-3 from normal huntingtin underlies mutant huntingtin neurotoxicity

10.1523/jneurosci.5831-12.2013 · 2013 · External reference

Huntingtin-Mediated Multipolar-Bipolar Transition of Newborn Cortical Neurons Is Critical for Their Postnatal Neuronal Morphology

10.1016/j.neuron.2016.11.035 · 2017 · External reference

Huntingtin and the Synapse

10.3389/fncel.2021.689332 · 2021 · External reference

The effects of multidisciplinary rehabilitation on neuroimaging, biological, cognitive and motor outcomes in individuals with premanifest Huntington’s disease

10.1016/j.jns.2020.117022 · 2020 · External reference

Huntingtin aggregation and toxicity in Huntington’s disease

10.1016/s0140-6736(03)13304-1 · 2003 · External reference

Huntington disease

10.1038/nrdp.2015.5 · 2015 · External reference

Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid

10.1523/jneurosci.13-10-04181.1993 · 1993 · External reference

Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner

10.1523/jneurosci.2126-08.2008 · 2008 · External reference

D1R- and D2R-Medium-Sized Spiny Neurons Diversity: insights Into Striatal Vulnerability to Huntington’s Disease Mutation

10.3389/fncel.2021.628010 · 2021 · External reference

Calcium signaling and neurodegenerative diseases

10.1016/j.molmed.2009.01.001 · 2009 · External reference

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease

10.1084/jem.20080178 · 2008 · External reference

The effects of modafinil on mood and cognition in Huntington’s disease

10.1007/s00213-008-1068-0 · 2008 · External reference

Pharmacologic Approaches for the Management of Apathy in Neurodegenerative Disorders

10.3389/fphar.2019.01581 · 2020 · External reference

Mutant huntingtin in glial cells exacerbates neurological symptoms of huntington disease mice

10.1074/jbc.m109.083287 · 2010 · External reference

Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS

10.1038/s41591-019-0674-1 · 2020 · External reference

Mitochondrial Permeability Transition: a Molecular Lesion with Multiple Drug Targets

10.1016/j.tips.2018.11.004 · 2019 · External reference

Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates

10.1073/pnas.92.15.7105 · 1995 · External reference

Recent advances in the management of choreas

10.1177/1756285612471700 · 2013 · External reference

A Systematic Review of Rehabilitation for Corticobulbar Symptoms in Adults with Huntington’s Disease

10.3233/jhd-190384 · 2020 · External reference

Late-onset Huntington’s disease with 40–42 CAG expansion

10.1007/s10072-019-04177-8 · 2020 · External reference

Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease

10.1016/j.jconrel.2024.01.011 · 2024 · External reference

Treating the whole body in Huntington’s disease

10.1016/s1474-4422(15)00177-5 · 2015 · External reference

Huntingtin as an essential integrator of intracellular vesicular trafficking

10.1016/j.tcb.2009.01.005 · 2009 · External reference

Huntingtin facilitates dynein/dynactin-mediated vesicle transport

10.1073/pnas.0610628104 · 2007 · External reference

The role of dopamine in huntington’s disease

10.1016/b978-0-444-63425-2.00010-6 · 2014 · External reference

What do we know about late onset Huntington’s disease?

10.3233/jhd-170247 · 2017 · External reference

Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons

10.1016/j.nbd.2005.12.007 · 2006 · External reference

Risk factors for the onset and progression of Huntington disease

10.1016/j.neuro.2017.01.005 · 2017 · External reference

Identification of preexisting adaptive immunity to Cas9 proteins in humans

10.1038/s41591-018-0326-x · 2019 · External reference

Dopamine imbalance in Huntington’s disease: a mechanism for the lack of behavioral flexibility

10.3389/fnins.2013.00114 · 2013 · External reference

Huntingtin-associated protein 1-associated intracellular trafficking in neurodegenerative diseases

2023 · External reference

Latest advances on new promising molecular-based therapeutic approaches for Huntington’s disease

10.2478/jtim-2023-0142 · 2024 · External reference

Reassessing mirtazapine and akathisia: a case report on its efficacy in treating severe, treatment-resistant akathisia and a review of the evidence

10.1177/2050313x241299947 · 2024 · External reference

Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington’s disease

2024 · External reference

CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington’s disease

10.1016/j.nbd.2009.07.014 · 2009 · External reference

Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease

10.1186/s40734-017-0051-5 · 2017 · External reference

Cognitive rehabilitation, self-management, psychotherapeutic and caregiver support interventions in progressive neurodegenerative conditions: a scoping review

10.3233/nre-172353 · 2019 · External reference

Treatment strategies for dystonia

10.1517/14656560903426171 · 2010 · External reference

Emerging Issues in AAV-Mediated In Vivo Gene Therapy

10.1016/j.omtm.2017.11.007 · 2018 · External reference

Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons

10.1038/emboj.2008.133 · 2008 · External reference

AAV1/2-mediated BDNF gene therapy in a transgenic rat model of Huntington’s disease

10.1038/gt.2015.113 · 2016 · External reference

Clinical and Molecular Features of Late Onset Huntington Disease in a Peruvian Cohort

10.3233/jhd-140119 · 2015 · External reference

The many faces of autophagy dysfunction in Huntington’s disease: from mechanism to therapy

10.1016/j.drudis.2014.02.014 · 2014 · External reference

A role for autophagy in Huntington’s disease

10.1016/j.nbd.2018.08.010 · 2019 · External reference

The choreography of neuroinflammation in Huntington’s disease

10.1016/j.it.2015.04.007 · 2015 · External reference

Oxidative stress and inflammation in the pathogenesis of neurological disorders: mechanisms and implications

10.1016/j.apsb.2024.10.004 · 2025 · External reference

RNA Interference: a Tool for Querying Nervous System Function and an Emerging Therapy

10.1016/j.neuron.2007.02.020 · 2007 · External reference

A novel triplet-primed pcr assay to detect the full range of trinucleotide cag repeats in the huntingtin gene (Htt)

10.3390/ijms22041689 · 2021 · External reference

Review of deutetrabenazine: a novel treatment for chorea associated with Huntington’s disease

10.2147/dddt.s138828 · 2018 · External reference

Role of hypokinesia and bradykinesia in gait disturbances in Huntington’s disease: a biomechanical study

10.1007/s00415-005-0929-2 · 2006 · External reference

Astrocyte molecular signatures in Huntington’s disease

10.1126/scitranslmed.aaw8546 · 2019 · External reference

Relationship between the use of benzodiazepines and falls in older adults: a systematic review

10.1016/j.maturitas.2017.04.002 · 2017 · External reference

Therapy development in Huntington disease: from current strategies to emerging opportunities

10.1002/ajmg.a.38494 · 2018 · External reference

Nuclear Localization of Huntingtin mRNA Is Specific to Cells of Neuronal Origin

10.1016/j.celrep.2018.07.106 · 2018 · External reference

Effect of early embryonic deletion of huntingtin from pyramidal neurons on the development and long-term survival of neurons in cerebral cortex and striatum

10.1016/j.nbd.2017.12.015 · 2018 · External reference

The potential of gene editing for Huntington’s disease

10.1016/j.tins.2023.02.005 · 2023 · External reference

Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity

10.1101/gad.1673408 · 2008 · External reference

Inactivation of the mouse huntington’s disease gene homolog Hdh

10.1126/science.7618107 · 1995 · External reference

Guidance on antipsychotic selection for agitation and aggressive behavior in persons with Huntington’s disease

10.1080/14737175.2024.2376836 · 2024 · External reference

Huntingtin phosphorylation governs BDNF homeostasis and improves the phenotype of Mecp2 knockout mice

10.15252/emmm.201910889 · 2020 · External reference

Huntington’s Disease and the Striatal Medium Spiny Neuron: cell-Autonomous and Non-Cell-Autonomous Mechanisms of Disease

10.1007/s13311-012-0112-2 · 2012 · External reference

CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington’s Disease Mouse Model

10.1016/j.omtn.2019.07.009 · 2019 · External reference

Protective Effects of Antioxidants in Huntington’s Disease: an Extensive Review

10.1007/s12640-018-9989-9 · 2019 · External reference

Genetic topography and cortical cell loss in Huntington’s disease link development and neurodegeneration

10.1093/brain/awad275 · 2023 · External reference

Huntington’s Disease Clinical Trials Corner: April 2022

10.3233/jhd-229002 · 2022 · External reference

Huntington’s Disease Clinical Trials Corner: November 2022

10.3233/jhd-229006 · 2022 · External reference

Huntington’s Disease Clinical Trials Corner: March 2024

10.3233/jhd-240017 · 2024 · External reference

Huntington’s Disease Clinical Trials Corner: August 2023

10.3233/jhd-239001 · 2023 · External reference

Glutamate toxicity in the striatum of the R6/2 Huntington’s disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters

10.1016/j.nbd.2008.12.017 · 2009 · External reference

AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington’s Disease Minipig Model

10.1016/j.ymthe.2018.06.021 · 2018 · External reference

In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington’s disease subjects

10.1093/hmg/ddq212 · 2010 · External reference

Huntington’s Disease Clinical Trials Update: september 2024

10.1177/18796397241293955 · 2024 · External reference

Huntington’s disease clinical trials update: march 2025

10.1177/18796397251337000 · 2025 · External reference

Novel Imaging Biomarkers for Huntington’s Disease and Other Hereditary Choreas

10.1007/s11910-018-0890-y · 2018 · External reference

Mitochondrial adaptor TRAK2 activates and functionally links opposing kinesin and dynein motors

10.1038/s41467-021-24862-7 · 2021 · External reference

Current and Possible Future Therapeutic Options for Huntington’s Disease

10.1177/11795735221092517 · 2022 · External reference

Unresolved reference

2008 · External reference

Huntington’s Disease

10.1101/cshperspect.a007476 · 2011 · External reference

Mitochondrial quality control in neurodegenerative diseases: focus on Parkinson’s disease and Huntington’s disease

2018 · External reference

Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators

10.1186/1471-2377-9-62 · 2009 · External reference

Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease

10.2147/ndt.s6430 · 2010 · External reference

Effect of deutetrabenazine on chorea among patients with huntington disease: A randomized clinical trial

10.1001/jama.2016.8655 · 2016 · External reference

Long-Term Efficacy and Safety of Deutetrabenazine for Chorea in Huntington’s Disease: results From the ARC-HD Open-label Study

10.1017/s1092852920002655 · 2021 · External reference

Physical Therapy and Exercise Interventions in Huntington’s Disease: a Mixed Methods Systematic Review

10.3233/jhd-170260 · 2017 · External reference

Supplemental Treatment for Huntington’s Disease with miR-132 that Is Deficient in Huntington’s Disease Brain

10.1016/j.omtn.2018.01.007 · 2018 · External reference

Natural history and burden of Huntington’s disease in the UK: a population-based cohort study

10.1111/ene.15385 · 2022 · External reference

Biological and clinical manifestations of juvenile Huntington’s disease: a retrospective analysis

10.1016/s1474-4422(18)30294-1 · 2018 · External reference

Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors

10.1136/jmg.2009.066399 · 2009 · External reference

The challenges and strategies of antisense oligonucleotide drug delivery

10.3390/biomedicines9040433 · 2021 · External reference

Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice

10.1073/pnas.1206506109 · 2012 · External reference

Huntington disease: advances in the understanding of its mechanisms

10.1016/j.prdoa.2020.100056 · 2020 · External reference

Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules

10.1016/j.cell.2004.06.018 · 2004 · External reference

RNA interference (RNAi)-based therapeutics for treatment of rare neurologic diseases

10.1016/j.mam.2022.101148 · 2023 · External reference

Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi

10.1038/ncb735 · 2002 · External reference

FAN1 modifies Huntington’s disease progression by stabilizing the expanded HTT CAG repeat

10.1093/hmg/ddy375 · 2019 · External reference

Stereopure ASOs: an unanticipated increase in selectivity for targeting mutant HTT

10.1016/j.omtn.2024.102312 · 2024 · External reference

Polyglutamine diseases and tansport problems

10.1001/archneur.62.1.46 · 2005 · External reference

Off-target effects in CRISPR/Cas9 gene editing

10.3389/fbioe.2023.1143157 · 2023 · External reference

Oxidative stress, mitochondrial damage and neurodegenerative diseases

2013 · External reference

The cryo-electron microscopy structure of huntingtin

10.1038/nature25502 · 2018 · External reference

Play it again, SAM: macrophages control peripheral fat metabolism

10.1016/j.it.2017.12.004 · 2018 · External reference

Neuroinflammation as a common feature of neurodegenerative disorders

10.3389/fphar.2019.01008 · 2019 · External reference

Botulinum Toxin in the Treatment of Cervical Dystonia

10.3389/dyst.2022.10655 · 2022 · External reference

Large animal models for Huntington’s disease research

2024 · External reference

Differential vulnerability of neurons in Huntington’s disease: the role of cell type-specific features

10.1111/j.1471-4159.2010.06672.x · 2010 · External reference

Glucose Metabolic Dysfunction in Neurodegenerative Diseases—New Mechanistic Insights and the Potential of Hypoxia as a Prospective Therapy Targeting Metabolic Reprogramming

10.3390/ijms22115887 · 2021 · External reference

Excess active P13K rescues huntingtin-mediated neuronal cell death but has no effect on axonal transport defects

10.1007/s10495-019-01520-4 · 2019 · External reference

Proteostasis in Huntington’s disease: disease mechanisms and therapeutic opportunities

10.1038/aps.2018.11 · 2018 · External reference

The hunt for huntingtin function: interaction partners tell many different stories

10.1016/s0968-0004(03)00168-3 · 2003 · External reference

RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model

10.1073/pnas.0501507102 · 2005 · External reference

Neuroinflammation and microglia: considerations and approaches for neurotoxicity assessment

10.1517/17425255.4.10.1265 · 2008 · External reference

KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia

10.1176/appi.ajp.2017.16091037 · 2017 · External reference

In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of huntington disease

10.1523/jneurosci.5599-08.2009 · 2009 · External reference

The distribution and density of Huntingtin inclusions across the Huntington disease neocortex: regional correlations with Huntingtin repeat expansion independent of pathologic grade

10.1186/s40478-022-01364-1 · 2022 · External reference

Microglia in neurodegeneration

10.1038/s41593-018-0242-x · 2018 · External reference

Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with β-tubulin: relevance to Huntington’s disease

10.1242/jcs.115.5.941 · 2002 · External reference

Genetic modifiers of Mendelian disease: huntington’s disease and the trinucleotide repeat disorders

10.1093/hmg/ddx261 · 2017 · External reference

De novo huntington disease caused by 26-44 CAG repeat expansion on a low-risk haplotype

10.1212/wnl.0b013e3182a4a4af · 2013 · External reference

A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in huntington’s disease

10.1093/hmg/ddt036 · 2013 · External reference

On Chorea

1872 · External reference

Cognition-oriented treatments and physical exercise on cognitive function in Huntington’s disease: a systematic review

10.1007/s00415-022-11516-x · 2023 · External reference

Clinical and Genetic Characteristics Associated With Survival Outcome in Late-Onset Huntington’s Disease in South Korea

10.3988/jcn.2023.0329 · 2024 · External reference

Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT

10.1016/j.omtn.2024.102246 · 2024 · External reference

Genetic Modifiers in Neurodegeneration

10.1007/s40142-018-0133-1 · 2018 · External reference

Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell-type-specific

10.1002/glia.23050 · 2017 · External reference

Neuroinflammation in Huntington’s disease: from animal models to clinical therapeutics

10.3389/fimmu.2022.1088124 · 2022 · External reference

From Pathogenesis to Therapeutics: a Review of 150 Years of Huntington’s Disease Research

10.3390/ijms241613021 · 2023 · External reference

Single nuclei RNA-seq reveals a medium spiny neuron glutamate excitotoxicity signature prior to the onset of neuronal death in an ovine Huntington’s disease model

2024 · External reference

Challenges in scaling up AAV-based gene therapy manufacturing

10.1016/j.tibtech.2023.04.002 · 2023 · External reference

Dynamics of Cortical Degeneration Over a Decade in Huntington’s Disease

10.1016/j.biopsych.2020.11.009 · 2021 · External reference

Seven cases of huntington’s disease in childhood and levodopa induced improvement in the hypokinetic — rigid form

10.1016/0303-8467(80)90017-7 · 1980 · External reference

The Polyglutamine Expansion at the N-Terminal of Huntingtin Protein Modulates the Dynamic Configuration and Phosphorylation of the C-Terminal HEAT Domain

10.1016/j.str.2020.06.008 · 2020 · External reference

Insights into the Pathogenesis of Neurodegenerative Diseases: focus on Mitochondrial Dysfunction and Oxidative Stress

10.3390/ijms222111847 · 2021 · External reference

Molecular Pathophysiological Mechanisms in Huntington’s Disease

10.3390/biomedicines10061432 · 2022 · External reference

Clinical Markers May Identify Patients at Risk for Early Parkinson’s Disease Dementia: a Prospective Study

10.1177/15333175211021369 · 2021 · External reference

Primary cilia and autophagic dysfunction in Huntington’s disease

10.1038/cdd.2015.80 · 2015 · External reference

Altered regulation of striatal neuronal N-methyl-D-aspartate receptor trafficking by palmitoylation in Huntington disease mouse model

10.3389/fnsyn.2019.00003 · 2019 · External reference

Irritability in Huntington’s Disease

10.3233/jhd-200397 · 2020 · External reference

Huntington’s Disease-Related Mortality Patterns: a Two-Decade Analysis of Mortality Trends in the United States, from 1999–2019

10.3233/jhd-240037 · 2024 · External reference

Epidemiology of Huntington disease

10.1016/b978-0-12-801893-4.00003-1 · 2017 · External reference

Bioenergetic deficits in Huntington’s disease iPSC-derived neural cells and rescue with glycolytic metabolites

2021 · External reference

Cellular Analysis of Silencing the Huntington’s Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice

10.3233/jhd-160215 · 2016 · External reference

AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease

10.1016/j.ymthe.2004.02.016 · 2004 · External reference

The HTT CAG-Expansion Mutation Determines Age at Death but Not Disease Duration in Huntington Disease

10.1016/j.ajhg.2015.12.018 · 2016 · External reference

Unravelling and Exploiting Astrocyte Dysfunction in Huntington’s Disease

10.1016/j.tins.2017.05.002 · 2017 · External reference

Oligonucleotide therapies for disorders of the nervous system

10.1038/nbt.3784 · 2017 · External reference

The role of IκB kinase complex in the neurobiology of Huntington’s disease

10.1016/j.nbd.2011.04.015 · 2011 · External reference

Survival of Korean Huntington’s Disease Patients

10.14802/jmd.16022 · 2016 · External reference

Posttranscriptional regulation of FAN1 by miR-124-3p at rs3512 underlies onset-delaying genetic modification in Huntington’s disease

10.1073/pnas.2322924121 · 2024 · External reference

Dysfunctional striatal dopamine signaling in Huntington’s disease

10.1002/jnr.24495 · 2019 · External reference

Huntingtin Aggregates and Mitochondrial Pathology in Skeletal Muscle but not Heart of Late-Stage R6/2 Mice

10.3233/jhd-180324 · 2019 · External reference

Sustained Therapeutic Reversal of Huntington’s Disease by Transient Repression of Huntingtin Synthesis

10.1016/j.neuron.2012.05.009 · 2012 · External reference

Late-onset Huntington’s disease: diagnostic and prognostic considerations

10.1016/j.parkreldis.2014.03.017 · 2014 · External reference

Huntington’s disease: pathogenesis to animal models

10.1016/s1734-1140(10)70238-3 · 2010 · External reference

Huntingtin and the molecular pathogenesis of Huntington’s disease

10.1038/sj.embor.7400250 · 2004 · External reference

Wild-type huntingtin protects neurons from excitotoxicity

10.1111/j.1471-4159.2005.03605.x · 2006 · External reference

Function and therapeutic value of astrocytes in neurological diseases

10.1038/s41573-022-00390-x · 2022 · External reference

Identification of genetic factors that modify clinical onset of huntington’s disease

10.1016/j.cell.2015.07.003 · 2015 · External reference

CAG repeat, not polyglutamine length, determines timing of Huntington’s disease onset

10.1016/j.cell.2019.06.036 · 2019 · External reference

Enhanced Ca2+-dependent glutamate release from astrocytes of the BACHD Huntington’s disease mouse model

10.1016/j.nbd.2013.06.002 · 2013 · External reference

Interaction of Huntington disease protein with transcriptional activator Sp1

10.1128/mcb.22.5.1277-1287.2002 · 2002 · External reference

Huntingtin-protein interactions and the pathogenesis of Huntington’s disease

10.1016/j.tig.2004.01.008 · 2004 · External reference

CRISPR-Cas9-mediated homology-directed repair for precise gene editing

10.1016/j.omtn.2024.102344 · 2024 · External reference

Reactive astrocytes: production, function, and therapeutic potential

10.1016/j.immuni.2017.06.006 · 2017 · External reference

Neurotoxic reactive astrocytes are induced by activated microglia

10.1038/nature21029 · 2017 · External reference

Impaired glutamate uptake in the R6 Huntington’s disease transgenic mice

10.1006/nbdi.2001.0430 · 2001 · External reference

The first patient with sporadic Huntington’s disease due to a de novo (CAG)n expansion in China

10.2478/jtim-2022-0006 · 2022 · External reference

Customizable virus-like particles deliver CRISPR–Cas9 ribonucleoprotein for effective ocular neovascular and Huntington’s disease gene therapy

10.1038/s41565-024-01851-7 · 2025 · External reference

Motor onset and diagnosis in Huntington disease using the diagnostic confidence level

10.1007/s00415-015-7900-7 · 2015 · External reference

Huntingtin silencing delays onset and slows progression of Huntington’s disease: a biomarker study

10.1093/brain/awab190 · 2021 · External reference

An evolutionary recent neuroepithelial cell adhesion function of huntingtin implicates ADAM10-Ncadherin

10.1038/nn.3080 · 2012 · External reference

Mitochondrial and Redox Modifications in Huntington Disease Induced Pluripotent Stem Cells Rescued by CRISPR/Cas9 CAGs Targeting

10.3389/fcell.2020.576592 · 2020 · External reference

Miro proteins coordinate microtubule- and actin-dependent mitochondrial transport and distribution

10.15252/embj.201696380 · 2018 · External reference

Amantadine in Huntington’s disease: open-label video-blinded study

10.1007/s100720200081 · 2002 · External reference

Huntingtin promotes cell survival by preventing Pak2 cleavage

10.1242/jcs.050013 · 2009 · External reference

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes

10.1016/0092-8674(93)90585-e · 1993 · External reference

Cause or compensation?—Altered neuronal Ca2+ handling in Huntington’s disease

10.1111/cns.12817 · 2018 · External reference

Amantadine in the akinetic-rigid variant of Huntington’s disease

10.1345/aph.1e004 · 2004 · External reference

Mitochondrial calcium uptake in organ physiology: from molecular mechanism to animal models

10.1007/s00424-018-2123-2 · 2018 · External reference

Impaired α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor trafficking and function by mutant Huntingtin

10.1074/jbc.m111.236521 · 2011 · External reference

The Huntington’s disease mutation impairs Huntingtin’s role in the transport of NF-κB from the synapse to the nucleus

10.1093/hmg/ddq358 · 2010 · External reference

Cargo recognition failure is responsible for inefficient autophagy in Huntington’s disease

10.1038/nn.2528 · 2010 · External reference

Cognitive phenotype and neurodegeneration associated with Tau in Huntington’s disease

10.1002/acn3.52031 · 2024 · External reference

Antipsychotic-induced movement disorders: evaluation and treatment

2005 · External reference

Base editing of trinucleotide repeats that cause Huntington’s disease and Friedreich’s ataxia reduces somatic repeat expansions in patient cells and in mice

2025 · External reference

Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the httQ140/Q140 mouse model of Huntington’s disease

10.1016/j.nbd.2019.104637 · 2020 · External reference

Huntington’s disease: a clinical review

10.1111/ene.13413 · 2018 · External reference

Tominersen in Adults with Manifest Huntington’s Disease

10.1056/nejmc2300400 · 2023 · External reference

Huntington’s disease

2024 · External reference

Splice modulators target PMS1 to reduce somatic expansion of the Huntington’s disease-associated CAG repeat

10.1038/s41467-024-47485-0 · 2024 · External reference

Rhes, a Striatal-selective Protein Implicated in Huntington Disease, Binds Beclin-1 and activates autophagy

10.1074/jbc.m113.536912 · 2014 · External reference

Prevalence and Incidence of Huntington’s Disease: an Updated Systematic Review and Meta‐Analysis

10.1002/mds.29228 · 2022 · External reference

Health services in Huntington disease: a systematic literature review

10.1212/cpj.0000000000200108 · 2023 · External reference

Genetic counseling in Huntington’s disease: potential new challenges on the horizon?

10.3389/fneur.2019.00453 · 2019 · External reference

Corticostriatal circuit dysfunction in Huntingtons disease: intersection of glutamate, dopamine and calcium

10.2217/fnl.10.41 · 2010 · External reference

Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington’s disease mice

10.1016/j.neuron.2010.01.008 · 2010 · External reference

AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease

10.1038/gt.2017.71 · 2017 · External reference

Early alterations of brain cellular energy homeostasis in huntington disease models

10.1074/jbc.m111.309849 · 2012 · External reference

Neuroinflammation in Huntington’s disease

10.1007/s00702-010-0430-7 · 2010 · External reference

CRISPR/Cas9 editing of the mutant huntingtin allele in vitro and in vivo

10.1016/j.ymthe.2016.11.010 · 2017 · External reference

Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington’s disease

10.1080/14737175.2024.2376107 · 2024 · External reference

Circadian and sleep disorder in Huntington’s disease

10.1016/j.expneurol.2012.10.014 · 2013 · External reference

Large genetic animal models of Huntington’s disease

10.3233/jhd-130050 · 2013 · External reference

What we don’t need to prove but need to do in multidisciplinary treatment and care in Huntington’s disease: a position paper

10.1186/s13023-023-02622-8 · 2023 · External reference

De novo expansion of a (CAG)n repeat in sporadic Huntington’s disease

10.1038/ng1093-168 · 1993 · External reference

Huntington disease: clinical, genetic, and social aspects

10.1177/089198879801100204 · 1998 · External reference

Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes

10.1016/0092-8674(95)90542-1 · 1995 · External reference

A phase 1/2, randomized, double-blind, sham control and open-label study to explore safety, tolerability, and efficacy signals of multiple doses of striatally-administered rAAV5-miHTT total huntingtin gene (HTT) lowering therapy (AMT-130)

2019 · External reference

A phase ib/II randomized, double-blind study to explore safety, tolerability, and efficacy signals of multiple doses of striatally-administered rAAV5-miHTT total huntingtin gene (HTT)

2021 · External reference

SCAMP5 links endoplasmic reticulum stress to the accumulation of expanded polyglutamine protein aggregates via endocytosis inhibition

10.1074/jbc.m807620200 · 2009 · External reference

Wild-type huntingtin regulates human macrophage function

10.1038/s41598-020-74042-8 · 2020 · External reference

Potential function for the Huntingtin protein as a scaffold for selective autophagy

10.1073/pnas.1420103111 · 2014 · External reference

Memantine use and cognitive decline in Huntington’s disease: an Enroll-HD study

10.1002/mdc3.13763 · 2023 · External reference

Impaired dopamine release and uptake in R6/1 Huntington’s disease model mice

10.1016/j.neulet.2011.01.036 · 2011 · External reference

Current status of PET imaging in Huntington’s disease

10.1007/s00259-016-3324-6 · 2016 · External reference

Recent approaches on Huntington’s disease

10.3892/br.2022.1587 · 2022 · External reference

Modulation of phospho‐CREB by systemically administered recombinant BDNF in the hippocampus of the R6/2 mouse model of huntington’s disease

2019 · External reference

The role of microglia and astrocytes in Huntington’s disease

10.3389/fnmol.2019.00258 · 2019 · External reference

Neuropsychiatric burden in huntington’s disease

10.3390/brainsci7060067 · 2017 · External reference

Unresolved reference

2023 · External reference

Valbenazine for the treatment of chorea associated with Huntington’s disease

10.1080/14656566.2024.2445728 · 2025 · External reference

Cognitive and behavioral changes in Huntington disease before diagnosis

10.1016/b978-0-12-801893-4.00006-7 · 2017 · External reference

Microglial activation correlates with severity in Huntington disease

10.1212/01.wnl.0000222734.56412.17 · 2006 · External reference

J001 Preliminary results from the first-in-human study of ER2001, an innovative treatment for Huntington’s disease using in vivo self-assembled sirna

2024 · External reference

Beyond CAG repeats: the multifaceted role of genetics in Huntington disease

10.3390/genes15060807 · 2024 · External reference

Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington’s Disease

10.1089/hum.2017.199 · 2018 · External reference

Advances in gene and cellular therapeutic approaches for Huntington’s disease

10.1093/procel/pwae042 · 2025 · External reference

Effects of a Two-Year Intensive Multidisciplinary Rehabilitation Program for Patients with Huntington’s Disease: a Prospective Intervention Study

2014 · External reference

In vivo CRISPR–Cas9 genome editing in mice identifies genetic modifiers of somatic CAG repeat instability in Huntington’s disease

10.1038/s41588-024-02054-5 · 2025 · External reference

Immune Responses and Immunosuppressive Strategies for Adeno-Associated Virus-Based Gene Therapy for Treatment of Central Nervous System Disorders: current Knowledge and Approaches

10.1089/hum.2022.138 · 2022 · External reference

The Assessment and Treatment of Antipsychotic-Induced Akathisia

10.1177/0706743718760288 · 2018 · External reference

What were you thinking? Individuals at risk for huntington disease talk about having children

10.1007/s10897-010-9312-2 · 2010 · External reference

The Prevalence of Juvenile Huntington’s Disease: a Review of the Literature and Meta-Analysis

10.1371/4f8606b742ef3 · 2012 · External reference

Clinical recommendations to guide physical therapy practice for Huntington disease

10.1212/wnl.0000000000008887 · 2020 · External reference

Adeno-associated Virus (AAV) versus immune response

10.3390/v11020102 · 2019 · External reference

Therapeutic in vivo delivery of gene editing agents

10.1016/j.cell.2022.03.045 · 2022 · External reference

Anticholinergics for neuroleptic-induced acute akathisia

2006 · External reference

Allelic Diversity, De Novo CAG Expansions and Intergenerational Instability at the HTT Locus in a Sample from India

2025 · External reference

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

10.1038/ng1362 · 2004 · External reference

Concern about Tominersen in Patients with Huntington’s Disease

10.1056/nejmc2400161 · 2024 · External reference

Wild-Type Huntingtin Plays a Role in Brain Development and Neuronal Survival

10.1385/mn:28:3:259 · 2003 · External reference

Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington’s disease knock-in striatal cells

10.1016/j.freeradbiomed.2014.06.023 · 2014 · External reference

Wild-type huntingtin protects from apoptosis upstream of caspase-3

10.1523/jneurosci.20-10-03705.2000 · 2000 · External reference

Huntingtin’s Neuroprotective Activity Occurs via Inhibition of Procaspase-9 Processing

10.1074/jbc.c100044200 · 2001 · External reference

The messenger RNAs for the N-methyl- d-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain

10.1016/0306-4522(96)00089-9 · 1996 · External reference

Antisense oligonucleotides: the next frontier for treatment of neurological disorders

10.1038/nrneurol.2017.148 · 2018 · External reference

Causes and Places of Death in a European Huntington’s Disease Prospective Cohort

10.1002/mdc3.12502 · 2017 · External reference

Review of Huntington’s Disease: from Basics to Advances in Diagnosis and Treatment

10.14740/jnr721 · 2022 · External reference

Regulation of intracellular trafficking of huntingtin-associated protein-1 is critical for TrkA protein levels and neurite outgrowth

10.1523/jneurosci.1251-06.2006 · 2006 · External reference

Antisense Oligonucleotide Therapy: from Design to the Huntington Disease Clinic

10.1007/s40259-022-00519-9 · 2022 · External reference

Huntington’s disease: a clinical review

10.1186/1750-1172-5-40 · 2010 · External reference

Huntington disease: natural history, biomarkers and prospects for therapeutics

10.1038/nrneurol.2014.24 · 2014 · External reference

Balancing needs as a family caregiver in Huntington’s disease: a qualitative interview study

10.1111/hsc.12174 · 2015 · External reference

Bradykinesia in Huntington’s disease

10.1097/00002826-200001000-00009 · 2000 · External reference

Huntington’s Disease: latest Frontiers in Therapeutics

10.1007/s11910-024-01345-y · 2024 · External reference

Neuroinflammation in Huntington’s Disease: a Starring Role for Astro-cyte and Microglia

10.2174/1570159x19666211201094608 · 2022 · External reference

Dose-dependent improvement of myoclonic hyperkinesia due to valproic acid in eight Huntington’s Disease patients: a case series

10.1186/1471-2377-6-11 · 2006 · External reference

Natural products proposed for the management of Huntington’s disease (HD): a comprehensive review

2025 · External reference

Update on ongoing therapeutic developments and a look toward the future

10.1016/j.parkreldis.2024.106049 · 2024 · External reference

Early and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain

10.1093/jnen/60.2.161 · 2001 · External reference

Huntington’s disease: the current state of research with peripheral tissues

10.1016/j.expneurol.2009.05.012 · 2009 · External reference

Defining the role of the Bcl-2 family proteins in Huntington’s disease

10.1038/cddis.2013.300 · 2013 · External reference

The Biology of Huntingtin

10.1016/j.neuron.2016.02.003 · 2016 · External reference

The biological function of the Huntingtin protein and its relevance to Huntington’s Disease pathology

2011 · External reference

Investigating the Effects of Brain Cholesterol Metabolism Using CYP46A1 Gene Therapy in Subjects with Huntington’s Disease (P1-11.016)

10.1212/wnl.0000000000203493 · 2023 · External reference

Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington’s disease

10.1016/j.pneurobio.2009.04.005 · 2010 · External reference

Antisense oligonucleotides: a primer

10.1212/nxg.0000000000000323 · 2019 · External reference

Tetrabenazine: for chorea associated with huntingtons disease

10.2165/11208330-000000000-00000 · 2011 · External reference

Unstable familial transmissions of Huntington disease alleles with 27–35 CAG repeats (intermediate alleles)

10.1002/ajmg.b.30970 · 2010 · External reference

A new mutation for Huntington disease following maternal transmission of an intermediate allele

10.1016/j.ejmg.2014.11.005 · 2015 · External reference

DNA double-strand break-free CRISPR interference delays Huntington’s disease progression in mice

10.1038/s42003-023-04829-8 · 2023 · External reference

Mechanisms of synaptic dysfunction and excitotoxicity in Huntington’s disease

10.1016/j.drudis.2014.02.006 · 2014 · External reference

RNAi: a potential new class of therapeutic for human genetic disease

10.1007/s00439-011-0995-8 · 2011 · External reference

Propranolol treatment for neuroleptic-Induced akathisia [2]

2005 · External reference

The Interplay of Axonal Energy Homeostasis and Mitochondrial Trafficking and Anchoring

10.1016/j.tcb.2017.01.005 · 2017 · External reference

Evidence-Based Review on Symptomatic Management of Huntington’s Disease

10.14802/jmd.24140 · 2024 · External reference

PAM-altering SNP-based allele-specific CRISPR-Cas9 therapeutic strategies for Huntington’s disease

10.1016/j.omtm.2022.08.005 · 2022 · External reference

Permanent inactivation of Huntington’s disease mutation by personalized allele-specific CRISPR/Cas9

2016 · External reference

Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity

10.1083/jcb.200508072 · 2005 · External reference

Mutant huntingtin’s interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington’s disease

10.1093/hmg/ddr475 · 2011 · External reference

Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington’s disease: implications for selective neuronal damage

10.1093/hmg/ddr024 · 2011 · External reference

Polyamines signalling pathway: a key player in unveiling the molecular mechanisms underlying Huntington’s disease

10.1016/j.neuroscience.2025.02.042 · 2025 · External reference

Distinct neuroinflammatory profile in post-mortem human Huntington’s disease

10.1097/wnr.0b013e32832e34ee · 2009 · External reference

Axonal transport and neurological disease

10.1038/s41582-019-0257-2 · 2019 · External reference

J004 ALN-HTT02, a novel C16-sirna conjugate for HTT-lowering in the CNS

2024 · External reference

Synaptic dysfunction in Huntington’s disease: a new perspective

10.1007/s00018-005-5084-5 · 2005 · External reference

The Neuropsychology of Huntington’s Disease

10.1093/arclin/acx086 · 2017 · External reference

Age at Death and Causes of Death in Patients with Huntington Disease in Norway in 1986–2015

10.3233/jhd-170270 · 2018 · External reference

Altered lactate metabolism in Huntington’s disease is dependent on GLUT3 expression

10.1111/cns.12837 · 2018 · External reference

Autophagy regulation by acetylation—implications for neurodegenerative diseases

10.1038/s12276-021-00556-4 · 2021 · External reference

Huntingtin suppression restores cognitive function in a mouse model of Huntington’s disease

10.1126/scitranslmed.aar3959 · 2018 · External reference

Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases

10.1016/j.molmed.2012.09.001 · 2012 · External reference

A fully humanized transgenic mouse model of Huntington disease

10.1093/hmg/dds397 · 2013 · External reference

AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models

10.1016/j.omtm.2019.03.002 · 2019 · External reference

Manufacturing Challenges and Rational Formulation Development for AAV Viral Vectors

10.1016/j.xphs.2021.03.024 · 2021 · External reference

Spinocerebellar Ataxia Type 3 Pathophysiology—Implications for Translational Research and Clinical Studies

10.3390/ijms25073984 · 2024 · External reference

Sex contribution to average age at onset of Huntington’s disease depends on the number of (CAG)n repeats

10.1038/s41598-024-64105-5 · 2024 · External reference

The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription

10.1073/pnas.100110097 · 2000 · External reference

J05 interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)

2022 · External reference

Wild-type huntingtin participates in protein trafficking between the Golgi and the extracellular space

10.1093/hmg/ddl467 · 2007 · External reference

Huntington’s disease: mortality and risk factors in an Australian cohort

10.1016/j.jns.2022.120437 · 2022 · External reference

Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-D-aspartate Receptors via Post-synaptic Density 95

10.1074/jbc.m103501200 · 2001 · External reference

Potential disease-modifying therapies for Huntington’s disease: lessons learned and future opportunities

10.1016/s1474-4422(22)00121-1 · 2022 · External reference

Huntingtin Lowering Strategies for Disease Modification in Huntington’s Disease

10.1016/j.neuron.2019.01.039 · 2019 · External reference

Targeting huntingtin expression in patients with Huntington’s disease

10.1056/nejmoa1900907 · 2019 · External reference

Microglial activation in presymptomatic Huntington’s disease gene carriers

10.1093/brain/awm044 · 2007 · External reference

Revisiting the neuropsychiatry of Huntington’s disease

10.1590/s1980-5764-2016dn1004002 · 2016 · External reference

Huntington disease: a quarter century of progress since the gene discovery

10.1016/j.jns.2018.09.022 · 2019 · External reference

Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington’s disease model mice

10.1038/nn.3691 · 2014 · External reference

Spatial and temporal requirements for huntingtin (Htt) in neuronal migration and survival during brain development

10.1523/jneurosci.2774-11.2011 · 2011 · External reference

Frédéric Saudou, Huntingtin associates with the actin cytoskeleton and α-actinin isoforms to influence stimulus dependent morphology changes

10.1371/journal.pone.0212337 · 2019 · External reference

HTT-lowering reverses Huntington’s disease immune dysfunction caused by NFκB pathway dysregulation

10.1093/brain/awt355 · 2014 · External reference

Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases

10.1016/j.neuroscience.2006.10.056 · 2007 · External reference

Molecular Mechanisms of Polyglutamine Pathology and Lessons Learned from Huntington’s Disease

2021 · External reference

Delivery of GABAARs to Synapses Is Mediated by HAP1-KIF5 and Disrupted by Mutant Huntingtin

10.1016/j.neuron.2009.12.007 · 2010 · External reference

Antipsychotic drugs in Huntington’s disease

10.1080/14737175.2016.1226134 · 2017 · External reference

Animal models of Huntington’s disease and their applicability to novel drug discovery and development

10.1080/17460441.2023.2201493 · 2023 · External reference

Lowering Mutant Huntingtin Levels and Toxicity: autophagy-Endolysosome Pathways in Huntington’s Disease

10.1016/j.jmb.2019.11.012 · 2020 · External reference

Beyond the brain: widespread pathology in Huntington’s disease

10.1016/s1474-4422(09)70178-4 · 2009 · External reference

Acetylcholinesterase inhibitors in cognitive impairment in Huntington’s disease: a brief review

10.5498/wjp.v3.i3.62 · 2013 · External reference

Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways

10.1006/exnr.1998.6832 · 1998 · External reference

A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington’s disease

10.1186/s13023-014-0114-8 · 2014 · External reference

Traffic signaling: new functions of huntingtin and axonal transport in neurological disease

10.1016/j.conb.2020.04.001 · 2020 · External reference

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

10.1016/s0140-6736(12)61729-2 · 2012 · External reference

Adeno-associated virus vector as a platform for gene therapy delivery

10.1038/s41573-019-0012-9 · 2019 · External reference

CRISPR-Based Therapeutic Genome Editing: strategies and In Vivo Delivery by AAV Vectors

10.1016/j.cell.2020.03.023 · 2020 · External reference

Adeno-associated virus as a delivery vector for gene therapy of human diseases

2024 · External reference

Significance of gene therapy in neurodegenerative diseases

2025 · External reference

Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington’s disease

10.1038/nm.3514 · 2014 · External reference

The pathobiology of perturbed mutant huntingtin protein–protein interactions in Huntington’s disease

10.1111/jnc.14853 · 2019 · External reference

CAG Expansion in the Huntington Disease Gene Is Associated with a Specific and Targetable Predisposing Haplogroup

10.1016/j.ajhg.2009.02.003 · 2009 · External reference

Huntingtin differentially regulates the axonal transport of a sub-set of Rab-containing vesicles in vivo

10.1093/hmg/ddv415 · 2015 · External reference

Therapies targeting DNA and RNA in Huntington’s disease

10.1016/s1474-4422(17)30280-6 · 2017 · External reference

The contribution of glial cells to Huntington’s disease pathogenesis

10.1016/j.nbd.2020.104963 · 2020 · External reference

Inactivation of the Huntington’s disease gene (Hdh) impairs anterior streak formation and early patterning of the mouse embryo

10.1186/1471-213x-5-17 · 2005 · External reference

Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system

10.1097/yic.0000000000000553 · 2025 · External reference

Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Hungtington’s disease

10.1093/hmg/10.17.1829 · 2001 · External reference

Transcriptional dysregulation and post-translational modifications in polyglutamine diseases: from pathogenesis to potential therapeutic strategies

10.3389/fnmol.2018.00153 · 2018 · External reference

Vectors in CRISPR Gene Editing for Neurological Disorders: challenges and Opportunities

10.1002/adbi.202400374 · 2025 · External reference

Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease

10.1016/s0092-8674(00)80623-6 · 2000 · External reference

Microglial activation in the pathogenesis of Huntington’s Disease

10.3389/fnagi.2017.00193 · 2017 · External reference

SQSTM1/p62 droplet -mediated autophagosome formation:insights into Huntington disease

10.1080/15548627.2021.1953820 · 2021 · External reference

CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease

10.1172/jci92087 · 2017 · External reference

Synaptic scale dopamine disruption in Huntington’s Disease model mice imageds with near infrared catecholamine nanosensors

2022 · External reference

A randomised feasibility study of computerised cognitive training as a therapeutic intervention for people with Huntington’s disease (CogTrainHD)

10.1186/s40814-020-00623-z · 2020 · External reference

Advantages and differences among various animal models of Huntington’s disease

10.20517/and.2024.13 · 2024 · External reference

Disrupted GABA AR trafficking and synaptic inhibition in a mouse model of Huntington’s disease

10.1016/j.nbd.2012.02.015 · 2012 · External reference

Treatment of Depression in Huntington’s Disease: a Systematic Review

10.1176/appi.neuropsych.20230120 · 2024 · External reference

Genomic analysis of reactive astrogliosis

10.1523/jneurosci.6221-11.2012 · 2012 · External reference

Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease

10.1038/s41591-019-0478-3 · 2019 · External reference

Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington’s disease gene homologue

10.1038/ng1095-155 · 1995 · External reference

In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets

10.1016/j.cell.2005.10.030 · 2005 · External reference

Huntingtin inhibits caspase-3 activation

10.1038/sj.emboj.7601445 · 2006 · External reference

Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease

10.1126/science.1059581 · 2001 · External reference

Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes

10.1038/ng1219 · 2003 · External reference

Molecular mechanisms and potential therapeutical targets in Huntington’s disease

10.1152/physrev.00041.2009 · 2010 · External reference